Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 90 days matching "pancreatic cancer"

🔴 BreakingDrug approvalEMAMay 11

New medicine to reduce triglycerides in adults with familial chylomicronaemia syndrome

The European Medicines Agency has approved a new medicine called Redemplo (plozasiran) for adults with familial chylomicronaemia syndrome (FCS), a rare genetic condition where the body cannot properly break down certain fats in the blood. This medicine helps reduce triglycerides, which are a type of fat that builds up to dangerous levels in people with FCS. The approval means the medicine is now available for patients in the European Union.

WHY IT MATTERSAdults with FCS in the EU now have access to a new treatment option that specifically targets triglyceride reduction, potentially reducing their risk of severe pancreatitis and other complications from extremely high blood fat levels.
→ You can act on thisfamilial chylomicronaemia syndrome
PipelineRSSMay 1

FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug

The FDA has given approval for Revolution Medicines to offer an experimental pancreatic cancer drug called daraxonrasib to patients outside of clinical trials through a special program called expanded access. This program allows patients with serious illnesses who have no other treatment options to try investigational drugs before they are fully approved. This is an important step forward for patients with pancreatic cancer who may benefit from this new treatment.

WHY IT MATTERSPatients with advanced pancreatic cancer who have exhausted standard treatment options may now have access to daraxonrasib through expanded access, potentially offering a new therapeutic option while the drug completes its clinical development.
💬 Ask your doctorpancreatic cancer
Clinical trialCLINICALTRIALSApr 14

Trial Now Recruiting: Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK) (NCT07524114)

Researchers are recruiting 7,000 cancer patients to test a new way of detecting cancer that comes back after treatment. By analyzing blood, tissue, and other body fluids for traces of cancer DNA, doctors hope to catch cancer earlier and help patients stay cancer-free longer. This study includes many types of cancer and will help doctors decide on the best treatment plans.

WHY IT MATTERSThis trial is now actively recruiting patients with various cancer types at a major Canadian cancer center, offering access to cutting-edge molecular residual disease testing that could detect cancer recurrence months before traditional imaging scans.
→ You can act on thisBreast CancerLung CancerMelanoma

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases